Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573728 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2CNR1CNR2POLBKDM4E | |
| SCHEMBL6442557 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2CNR1CNR2POLBKDM4E | |
| SCHEMBL3588860 | 0.83 | SMN1; SMN2 (0.36) | SMN1; SMN2CNR1CNR2MAPTALDH1A1 | |
| SCHEMBL27492967 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2CNR1CNR2POLBKDM4E | |
| SCHEMBL28550994 | 0.80 | ALDH1A1 (0.33) | CNR1CNR2POLBKDM4EALDH1A1 | |
| SCHEMBL3576811 | 0.80 | ALDH1A1 (0.36) | CNR1CNR2ALDH1A1CYP1A2 | |
| SCHEMBL6200618 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2CNR1CNR2POLBKDM4E | |
| SCHEMBL6363517 | 0.78 | GAA (0.46) | SMN1; SMN2POLBKDM4EL3MBTL1KMT2A | |
| SCHEMBL3579717 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2CNR1CNR2POLBKDM4E | |
| SCHEMBL331219 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2CNR1CNR2POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| CN-100383141-C | Pyrazolo [4,3-d] pyrimidine derivatives | PFIZER (US) | 2008-04-23 | — | — | CN | disclosed |
| CN-100378100-C | Pyrazolo(4,3-d)pyrimidine derivatives | PFIZER (US) | 2008-04-02 | — | — | CN | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PFIZER INC | 2006-12-28 | — | — | US | disclosed |
| CN-1680378-A | Pyrazolo(4,3-d)pyrimidine derivatives | PFIZER (US) | 2005-10-12 | — | — | CN | disclosed |
| CN-1207297-C | Crystalline therapeutic agents | PFIZER LTD (US) | 2005-06-22 | — | — | CN | disclosed |
| EP-1222190-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| US-6420557-B1 | FOR THERAPY OF MALE ERECTILE DYSFUNCTION | PFIZER INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | disclosed |
| US-6407259-B1 | REACTING DIETHER COMPOUND WITH ACYLATING AGENT COMPRISING ACID ANHYDRIDE OR ACID HALIDE DERIVATIVE TO FORM PYRAZOLE DERIVATIVE | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PFIZER INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | PFIZER INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2002010171-A1 | CRYSTALLINE THERAPEUTIC AGENT | PFIZER LIMITED (GB) | 2002-02-07 | — | — | WO | disclosed |
| EP-1176142-A1 | Process for the preparation of pyrazoles | PFIZER INC. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001027112-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1628/4885CNR1 1668/4885CNR2 2125/4885 |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1628/4885CNR1 1668/4885CNR2 2125/4885 |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | SMN1; SMN2 4419/4885CNR1 2587/4885CNR2 2454/4885 |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PDE3A, PDE5A, PDE3B | SMN1; SMN2 1200/4885CNR1 1439/4885CNR2 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.